Jennison Associates
MRTX

Jennison Associates’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Jennison Associates’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-257,939
Closed -$37.8M – 726
2021
Q4 		$37.8M Sell
257,939
-4,382
-2% -$680K 0.02% 269
2021
Q3 		$46.4M Buy
262,321
+89,329
+52% +$14.4M 0.03% 232
2021
Q2 		$27.9M Buy
172,992
+89,395
+107% +$14.4M 0.02% 324
2021
Q1 		$14.3M Buy
+83,597
New +$16.6M 0.01% 389
2020
Q3 		– Sell
-504,451
Closed -$57.6M – 701
2020
Q2 		$57.6M Sell
504,451
-78,468
-13% -$7.61M 0.05% 147
2020
Q1 		$44.8M Sell
582,919
-4,768
-0.8% -$428K 0.05% 156
2019
Q4 		$75.7M Sell
587,687
-132,714
-18% -$12.8M 0.08% 142
2019
Q3 		$56.1M Sell
720,401
-246,930
-26% -$23.2M 0.06% 179
2019
Q2 		$99.6M Sell
967,331
-225,348
-19% -$17.5M 0.1% 118
2019
Q1 		$87.4M Sell
1,192,679
-23,785
-2% -$1.62M 0.09% 133
2018
Q4 		$51.6M Buy
1,216,464
+217,960
+22% +$8.69M 0.06% 202
2018
Q3 		$47M Buy
998,504
+383,785
+62% +$21.4M 0.04% 262
2018
Q2 		$30.3M Buy
614,719
+86,323
+16% +$3.26M 0.03% 342
2018
Q1 		$16.2M Buy
528,396
+40,797
+8% +$1.13M 0.02% 416
2017
Q4 		$8.9M Buy
+487,599
New +$7.57M 0.01% 470
2016
Q2 		– Sell
-65,789
Closed -$1.41M – 665
2016
Q1 		$1.41M Buy
65,789
+535
+0.8% +$12K ﹤0.01% 546
2015
Q4 		$2.06M Buy
65,254
+254
+0.4% +$8.97K ﹤0.01% 559
2015
Q3 		$2.24M Buy
+65,000
New +$1.96M ﹤0.01% 591

Other funds holding MRTX

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Jennison Associates's MRTX Position: Q1 2022 in Review

Jennison Associates sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2022, closing a stake of 257,939 shares — an estimated $37.8M sold.

Jennison Associates first reported a position in MRTX in Q3 2015 and held it in 18 quarters. The position peaked at $99.6M in Q2 2019. 253 funds tracked by Wall St. Rank hold MRTX as of Q1 2022.

  • Jennison Associates reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • Jennison Associates sold 257,939 Mirati Therapeutics, Inc. Common Stock shares in Q1 2022, an estimated $37.8M.
  • Jennison Associates first reported a position in Mirati Therapeutics, Inc. Common Stock in Q3 2015 and held it in 18 quarters.
  • Jennison Associates's Mirati Therapeutics, Inc. Common Stock position peaked at $99.6M in Q2 2019.
  • 253 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2022.

Based on Jennison Associates's 13F filing for Q1 2022, filed 11 May 2022.